Skip to main content
OpenTrials
Completed

NCT Number: NCT06787170

Prediction of Platinum Resistance and Prognosis of High-grade Serous Ovarian Cancer

High-grade serous ovarian carcinoma (HGSOC) is the most common subtype of ovarian carcinoma. Platinum-based drugs are the first-line chemotherapeutic agents for HGSOC, but platinum resistance and prognosis are difficult to predict. Domestic and foreign studies have found that multi-functional MRI could reflect the macroscopic heterogeneity of tumors from different perspectives; habitat imaging contributed to reflecting the spatial heterogeneity of tumors; the attention mechanism could integrate features of different scales; and multi-omics were capable to improve predictive performance. Previously, our team has demonstrated the importance of MRI and its functional imaging in the diagnosis and histological evaluation of gynecological tumors. And conventional MRI habitat imaging, multi-instance learning based on whole slide image (WSI), and multi-omics model could effectively predict platinum resistance in HGSOC patients. Therefore, this study aims to perform habitat imaging on multi-functional MRI such as multi b-value DWI and DCE-MRI and to train WSI-based multi-instance learning to construct pathological signature. Then, combined with clinical indicators, radiomics based on MRI habitat, and pathomics, a multi-omics fusion model trained by attention mechanism was constructed. Finally, to explore the value of MRI habitat, WSI, and multi-omics in predicting platinum resistance and prognosis in HGSOC patients. This study combines macroscopic functional imaging and microscopic pathological information to construct a multi-omics complementary model, which can predict platinum resistance and prognosis of HGSOC patients more comprehensively and accurately, and further guide the formulation of clinical treatment.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

Female

Study type

Observational

Primary location

the First People's Hospital of Yunnan Province

Kunming, Yunnan, 400016, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients diagnosed as HGSOC based on surgery and pathology.
  • The standard treatment including surgical cytoreduction followed by at least three cycles of regular platinum-based chemotherapy after surgery.
  • Follow-up records available for more than six months after postoperative chemotherapy.
  • For MRI analysis, pelvic MRI examination including axial T2-weighted imaging (T2WI), contrast-enhanced T1-weighted imaging (CE-T1WI), and diffusion-weighted imaging (DWI) was performed within two weeks prior to treatment, and patients had no any treatments other than neoadjuvant chemotherapy (NACT) performed between MRI and surgery.

Exclusion criteria

  • Patients with a history of platinum-based chemotherapy for other malignancies.
  • Absence of essential clinical data.
  • For MRI analysis, patients with poor MRI imaging quality and registration, or a tumor maximum diameter < 1 cm on MRI needed to be excluded.
  • For pathology analysis, patients without H&E-stained WSIs or with poor WSI imaging quality should be excluded.

Treatment and study plan

MRI habitat imaging

Diagnostic Test

Habitat imaging, a data-driven image processing technique that divides the entire lesion into multiple sub-regions without assuming anything prior, has capacity to noninvasively evaluate the intratumoral heterogeneity.

Other names: radiopathomics

Primary outcomes

  1. platinum resistance

    Time frame: within 6 months

    Platinum resistance is determined based on whether there is disease progression during or within 6 months after termination of platinum-based chemotherapy.

Sponsors and collaborators

Lead sponsor

The First People's Hospital of Yunnan

Other

Registry information

Official study title

Prediction of Platinum Resistance and Prognosis in Patients with High-grade Serous Ovarian Cancer Based on MRI Habitat Imaging and Radiopathomics

Acronym: PPRPHGSOC

Important dates

Study start
2022
Primary completion
2023
Study completion
2024
First posted
Jan 22, 2025
Registry last updated
Jan 23, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.